Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 31;18(1):2024416.
doi: 10.1080/21645515.2021.2024416. Epub 2022 Feb 7.

CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy

Arne Billmeier  1 , Krutika Khinvasara  2 , Franziska Lang  2 , Julia Mohr  1 , Daniel Reidenbach  2 , Maik Schork  2 , Ikra Yildiz  2 , Mustafa Diken  1   2
Affiliations

CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy

Arne Billmeier et al. Hum Vaccin Immunother. .

Abstract

After one year of absence, the 18th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Europe's cancer immunotherapy meeting, took place virtually from 10 to 12 May 2021. Over 850 academic and clinical professionals from 30 countries met to discuss the recent advancements in cancer immunotherapy and the current progress in COVID19-related research. This meeting report summarizes the highlights of CIMT2021.

Keywords: CIMT; Covid19; cancer immunotherapy; cellular therapy; checkpoint blockade; combination therapy; personalized therapy; tumor microenvironment; tumor vaccination.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

References

    1. Martínez Bedoya D, Dutoit V, Migliorini D.. Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front Immunol. 2021;12:640082. eng. doi:10.3389/fimmu.2021.640082. - DOI - PMC - PubMed
    1. Stenger D, Stief TA, Kaeuferle T, Willier S, Rataj F, Schober K, Vick B, Lotfi R, Wagner B, Grünewald TGP, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood. 2020;136(12):1407–10. eng. doi:10.1182/blood.2020005185. - DOI - PMC - PubMed
    1. Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374). eng. doi:10.1126/scitranslmed.aaj2013. - DOI - PubMed
    1. Jahn L, Hombrink P, Hagedoorn RS, Kester MGD, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, et al. TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood. 2017;129(10):1284–1295. eng. doi:10.1182/blood-2016-09-737536. - DOI - PubMed
    1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. eng. doi:10.4065/78.1.21. - DOI - PubMed

Publication types